John M. Burke, MD, is the Associate Chair of the Hematology Research Program at US Oncology, and a medical oncologist/hematologist at the Rocky Mountain Cancer Centers in Boulder, Colorado. He specializes in blood cancers, with an emphasis on lymphoid
disorders, including lymphomas, chronic lymphocytic leukemia (CLL), and multiple myeloma.
Dr. Burke is considered a national and international expert in blood cancers, lecturing primarily on lymphoid malignancies. He is very active in clinical research, helping to develop new therapies for lymphoid malignancies, and has published numerous
articles in peer-reviewed medical journals, including the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology. He currently serves as Editor-in-Chief for Targeted Therapies in Oncology and as an Associate Editor for JCO Oncology
Practice. He is active in hematology and oncology professional societies, having recently served a term on the Ethics Committee of the American Society of Clinical Oncology (ASCO) and currently serving a term on the Committee on Practice of the American
Society of Hematology (ASH). He serves as chair of the US Oncology Pathways Task Force.
Dr. Burke earned his undergraduate degree from Harvard University, where he graduated magna cum laude with an A.B. in History and Science. Dr. Burke went on to earn his medical degree from the Baylor College of Medicine in Houston. He completed a residency
in Internal Medicine at the University of California at San Francisco, and a fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center in New York City.
Kirollos Hanna, PharmD, BCPS, BCOP, is the Director of Pharmacy at Minnesota Oncology and an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine. Dr. Hanna also serves as an Associate Editor for the Journal of the Advanced Practitioner in Oncology (JADPRO).
Dr. Hanna’s research interests are focused on B-cell malignancies and genitourinary cancers. He has published over a dozen peer-reviewed manuscripts in various journals including Pharmacotherapy, AJHP, Drugs, JOPP, AJMC and JHOP.
Dr. Hanna is board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He received his Doctor of Pharmacy from Florida A&M University, completed his general residency at St. Thomas Hospital, Nashville, TN and his oncology residency at St. Luke's Mountain States Tumor Institute, Boise, ID.
Jeff Sharman, MD, is the Medical Director of Hematology Research at US Oncology, and the Director of Research at the Willamette Valley Center Institute in Eugene, Oregon. Dr. Sharman also helps to lead the Sarah Cannon Hematology program. He helped develop the science for B-cell receptor signal inhibitors. He has helped develop multiple BTK inhibitors, PI3K inhibitors, polatuzumab, venetoclax, obinutuzumab among others.
Dr. Sharman earned a medical degree from UC Davis in Davis, California. He completed a residency in internal medicine from Massachusetts General Hospital in Boston, Massachusetts, and a fellowship with Stanford University in Stanford, California. He earned a bachelor's degree in biochemistry from UC San Diego in San Diego, California.
In partnership with the Leukemia & Lymphoma Society
Funding and support provided by Eli Lilly